Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

he end-user customer.  Cadence recognized this deferred revenue during the period as it determined it had obtained sufficient product return history as of January 1, 2013, to reasonably estimate future wholesaler returns. As a result, the company recorded a one-time adjustment during the three months ended March 31, 2013, to recognize deferred revenue on previously shipped product, resulting in additional net revenue of $2.6 million and cost of sales of $0.9 million, for a net gross margin impact of $1.7 million.

For the three months ended March 31, 2013, Cadence reported a net loss of $1.4 million, or $0.02 per share, compared to a net loss of $22.7 million, or $0.27 per share, for the comparable period in 2012. Included in the company's net loss for the three months ended March 31, 2013, was a gain of $7.7 million Cadence recorded on the waiver, termination and sale of its Incline assets in January 2013, for which the company received cash payments totaling $14.6 million. Excluding the $7.7 million gain from the Incline transaction, and the $1.7 million gross margin impact from the change in the company's revenue recognition accounting estimate, Cadence's net loss for the three months ended March 31, 2013, was $10.8 million, or $0.13 per share.

Gross margin for the three months ended March 31, 2013, was 65%, compared to 47% for the comparable period in 2012. The increase in margin was primarily a result of higher freight costs incurred during the first quarter of 2012 that were not incurred in 2013, the impact of price increases implemented in July 2012 and January 2013, and a one-time credit of $0.3 million recorded during the three months ended March 31, 2013, in connection with the termination of the company's supply agreement with Baxter. Operating expenses, including patent amortization, decreased $2.0 million for the three months ended March 31, 2013, to $23.4 million, from $25.4 million for the same period in 2012. This decrease in
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
(Date:10/22/2014)... -- Research and Markets  has announced the addition ... Application, Geography - Global Analysis and Forecast (2014 - ... Organic electronics, also called as polymer electronics or plastic ... with small conductive molecules and electrically conductive polymers. It ... are carbon based, made using synthetic strategies developed in ...
(Date:10/20/2014)... 20, 2014 The report “Pharmacy ... Systems, Packaging and Labeling Systems, Table-top Counters) by ... Global Forecasts & Trends to 2019” analyzes and ... in North America, Europe, Asia-Pacific, and the Rest ... tables and 30 figures spread through 300 pages ...
(Date:10/20/2014)... October 20, 2014 Convey Computer ... a team from Iowa State University won first place ... Using a Convey HC-2ex, the team’s solution achieved the ... faster than the second place finisher. , Experts from ... upon the month long challenge, using a variety of ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... funded by the Biotechnology and Biological Sciences Research Council (BBSRC), ... new type of vaccine to protect chickens against coccidiosis, the ... of this type -- based on proteins from the coccidiosis ... could be produced on a larger scale than is currently ...
... of researchers has invented new artificial muscles strong enough to ... the same flexibility of an elephant,s trunk or octopus limbs. ... Express, the scientists and engineers from the University of ... of Texas at Dallas and Hanyang University in Korea detail ...
... MANSFIELD, Mass., Oct. 13, 2011 PrimeraDx today announced ... President of Corporate Development.   "Jeff,s diverse ... a great addition to the leadership team," Said Matt ... leverage the multimodal capabilities of the ICE Plex ...
Cached Biology Technology:A step towards new vaccines for most important chicken parasite 2A step towards new vaccines for most important chicken parasite 3UBC researchers invent tiny artificial muscles with the strength, flexibility of elephant trunk 2PrimeraDx Appoints Jeff Liter as VP of Corporate Development 2
(Date:10/16/2014)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market announces ... the Smart Wallet, at the 13 th annual ... global conference on the intersection of technology and the ... , founder and publisher of the Strategic News Service™, ...
(Date:10/15/2014)... spreading rapidly and to an unexpected extent. The outbreak ... and the virus shows a new disease dynamic in ... this reason, the German National Academy of Sciences Leopoldina, ... and the Union of the German Academies of Sciences ... epidemic today. , In the statement the academies call ...
(Date:10/14/2014)... thieves, prostate cancer tumors scavenge and hoard copper that ... avarice may be a fatal weakness. , Researchers ... prostate cancer cells by delivering a trove of copper ... cells brimming with the mineral, leaving non-cancer cells healthy. ... commercially available for other uses, could soon be tested ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
... , April 27 Tyco International Ltd. (NYSE: ... of its Electrical & Metal Products business. Tyco expects to file documents ... months and to complete the proposed transaction in the first half of ... traded U.S. company. , , ...
... , April 27 The Breema Center today ... Germany the 12-16 of May, 2010. Breema is a ... emphasizes the mind-body connection.  The Intensive program is designed to ... long time students deepen their understanding of Breema and its ...
... Debt advice specialists at MoneySolve believe that the record level of personal ... of financial management and debt education. , ... More than 134,000 people became insolvent during 2009, by entering ... to experience severe financial difficulties. Experts at MoneySolve believe that by increasing ...
Cached Biology News:Tyco International To Pursue Spin-Off of Electrical & Metal Products Business 2Tyco International To Pursue Spin-Off of Electrical & Metal Products Business 3Breema Center to Host International Intensive Week in Buhl, Germany 2Breema Center to Host International Intensive Week in Buhl, Germany 3
... Note: Protein determined by Biuret Physical form: ... Tris-HCl, pH 7.6, 1 mM MgCl 2 ... Preparation Unit Definition: One unit will hydrolyze ... at pH 9.8 at 37 C. • ...
... Varioskan is a high performance ... dispenser and incubator. With the advanced ... and reliability for drug discovery assay ... for fluorescence intensity, time-resolved fluorescence and ...
Immulon 2 HB 1x8 Strip assembled, C-bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes....
... RCT series of refrigerated cold traps offers ... of low volatility/aqueous solvents or high volatility ... other vacuum concentrators/centrifugal evaporators. Also used for ... such as used in electron microscopes. Can ...
Biology Products: